Child: For relief of signs and symptoms: As tab or cap: ≥6 years weighing 22-31 kg: 600 mg once daily; 32-54 kg: 900 mg once daily; ≥55 kg: 1,200 mg once daily. Max: 1,200 mg daily. All daily doses may be divided if the patient cannot tolerate the once-daily dosing. Use the lowest effective dose for the shortest possible duration.
Oral Osteoarthritis, Rheumatoid arthritis
Adult: For relief of signs and symptoms: As tab or cap: 1,200 mg once daily. Max dose for tab: 1,800 mg daily or 26 mg/kg daily (whichever is lower), given in divided doses. Max dose for cap: 1,200 mg daily. All daily doses may be divided if the patient cannot tolerate the once-daily dosing. Patients with low body weight: Initially, 600 mg once daily. Use the lowest effective dose for the shortest possible duration.
Renal Impairment
Osteoarthritis; Rheumatoid arthritis:
Severe or patients on haemodialysis: Initially, 600 mg once daily, may be increased to 1,200 mg once daily if necessary. Use the lowest effective dose for the shortest possible duration.
Contraindications
Hypersensitivity. History of asthma, urticaria, or other allergic-type reactions to aspirin or other NSAIDs. Use in the setting of CABG surgery.
Special Precautions
Patient with known CV disease or its risk factors; history of peptic ulcer disease or gastrointestinal bleeding; asthma (without known aspirin sensitivity), coagulation disorders, hypertension, dehydration, hypovolaemia. Smokers. Patients undergoing surgical or dental procedures. Avoid use in patients with active gastrointestinal bleeding, recent MI, or severe heart failure (unless benefits outweigh the risks). Oxaprozin dosage strength and formulations, particularly the tab and cap forms, are not interchangeable. Renal and hepatic impairment. Children and elderly. Pregnancy and lactation. Concomitant use with aspirin, anticoagulants, oral corticosteroids, SSRIs and SNRIs.
Adverse Reactions
Significant: Haematologic effects (e.g. decreased platelet adhesion and aggregation, prolonged bleeding time, anaemia); hyperkalaemia, mild photosensitivity reactions; new-onset or worsening of existing hypertension; CNS effects (e.g. drowsiness, dizziness, blurred vision); renal papillary necrosis or other renal injury (prolonged use), increased ALT/AST levels; fluid retention or oedema. Ear and labyrinth disorders: Tinnitus. Gastrointestinal disorders: Abdominal pain, constipation, diarrhoea, flatulence, dyspepsia, heartburn, nausea, vomiting. Metabolism and nutrition disorders: Anorexia. Nervous system disorders: Headache. Psychiatric disorders: Sleep disturbance. Renal and urinary disorders: Dysuria, urinary frequency. Skin and subcutaneous tissue disorders: Rash, pruritus. Potentially Fatal: Anaphylactoid/anaphylactic reactions; drug reaction with eosinophilia and systemic symptoms (DRESS), serious skin reactions (e.g. Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, generalised bullous fixed drug eruption); serious gastrointestinal events, including gastrointestinal inflammation, bleeding, ulceration, and perforation of oesophagus, stomach or intestines; CV thrombotic events (e.g. MI, stroke). Rarely, severe hepatic injury (e.g. liver necrosis, fulminant hepatitis, hepatic failure).
PO: Z (NSAIDs caused foetal ductus arteriosus premature closure, foetal renal impairment and persistent pulmonary hypertension. Avoid near term, else use lowest dose for shortest time.)
Patient Counseling Information
This drug may cause drowsiness, dizziness, and blurred vision, if affected, do not drive or operate machinery.
Monitoring Parameters
Monitor blood pressure, CBC, hepatic and renal function, and serum potassium levels, especially for prolonged use. Assess for signs and symptoms of DRESS (e.g. fever, rash, lymphadenopathy, eosinophilia), serious skin reactions, hepatotoxicity and gastrointestinal ulceration or bleeding.
Overdosage
Symptoms: Lethargy, drowsiness, nausea, vomiting, epigastric pain and gastrointestinal bleeding. Rarely, hypertension, acute renal failure, respiratory depression, or coma. Management: Symptomatic and supportive treatment. May consider induction of emesis or administration of activated charcoal for patients presenting within 4 hours of ingesting large overdoses.
Drug Interactions
May diminish the antihypertensive effects of ACE inhibitors, ARBs, and β-blockers (e.g. propranolol). May decrease the natriuretic effect of loop (e.g. furosemide) and thiazide diuretics. May increase the serum concentrations of digoxin, lithium, and methotrexate. May increase the nephrotoxic effect of ciclosporin. May increase the myelosuppressive effect and the renal or gastrointestinal toxicity of pemetrexed. Potentially Fatal: Increased risk of bleeding events, including gastrointestinal ulceration or bleeding with other NSAIDs, anticoagulants (e.g. warfarin), aspirin, oral corticosteroids, SSRIs and SNRIs.
Food Interaction
May increase the risk of gastrointestinal bleeding with alcohol.
Lab Interference
May cause false-positive result in urine immunoassay screening test for benzodiazepines. May result in false-positive aldosterone/renin ratio.
Action
Description: Mechanism of Action: Oxaprozin is a propionic acid derivative NSAID that has antipyretic, analgesic, and anti-inflammatory properties. It reversibly inhibits the cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, resulting in the reduced formation of prostaglandin precursors. Pharmacokinetics: Absorption: Slowly but extensively absorbed from the gastrointestinal tract. Time to peak plasma concentration: Approx 2-3 hours. Distribution: Distributes into synovial tissues. Volume of distribution: 11-17 L/70 kg. Plasma protein binding: 99%, mainly to albumin. Metabolism: Metabolised in the liver via microsomal oxidation and conjugation with glucuronic acid into inactive metabolites. Excretion: Via urine (65% as metabolites, 5% as unchanged drug); faeces (35% as metabolites). Elimination half-life: 41-55 hours.
Chemical Structure
Oxaprozin Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 4614, Oxaprozin. https://pubchem.ncbi.nlm.nih.gov/compound/Oxaprozin. Accessed Aug. 26, 2025.
M01AE12 - oxaprozin ; Belongs to the class of propionic acid derivatives of non-steroidal antiinflammatory and antirheumatic products.
References
Brayfield A, Cadart C (eds). Oxaprozin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 11/08/2025.Coxanto Capsules (Solubiomix). U.S. FDA. https://www.fda.gov. Accessed 12/08/2025.Oxaprozin Capsule (Ayurax, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 22/08/2025.Oxaprozin Tablet (Amneal Pharmaceuticals NY LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 11/08/2025.Oxaprozin. UpToDate Lexidrug, AHFS DI (Adult and Pediatric) Online. American Society of Health-System Pharmacists, Inc. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 11/08/2025.Oxaprozin. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 11/08/2025.
Sign Out
Continue with Google